P

ProKidney Corp
NASDAQ:PROK

Watchlist Manager
ProKidney Corp
NASDAQ:PROK
Watchlist
Price: 2.16 USD -0.92%
Market Cap: $649.8m

Net Margin

-9 547.4%
Current
Improving
by 21 995%
vs 3-y average of -31 542.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-9 547.4%
=
Net Income
$-71m
/
Revenue
$744k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-9 547.4%
=
Net Income
$-71m
/
Revenue
$744k

Peer Comparison

Country Company Market Cap Net
Margin
US
ProKidney Corp
NASDAQ:PROK
643.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
166.3B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4th
Based on 15 072 companies
4th percentile
-9 547.4%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

ProKidney Corp
Glance View

Market Cap
649.8m USD
Industry
Biotechnology

ProKidney Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Winston-Salem, North Carolina and currently employs 0 full-time employees. The company went IPO on 2021-06-30. ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The firm is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The firm is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.

PROK Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-9 547.4%
=
Net Income
$-71m
/
Revenue
$744k
What is ProKidney Corp's current Net Margin?

The current Net Margin for ProKidney Corp is -9 547.4%, which is above its 3-year median of -31 542.4%.

How has Net Margin changed over time?

Over the last 9 months, ProKidney Corp’s Net Margin has increased from -80 507.9% to -9 547.4%. During this period, it reached a low of -80 507.9% on Dec 31, 2024 and a high of -9 547.4% on Oct 30, 2025.

Back to Top